Malaria patients enter DNDi clinical trials.(Essential Medicines)

A year after its launch, the Drugs for Neglected Diseases Initiative (DNDi) is starting clinical trials of two fixed-dose drug combinations against malaria. To ensure a balanced portfolio of drugs in the pipeline, DNDi mixes quick-fix with long-term projects. In the short term, DNDi is developing fixed-dose combinations for uncomplicated malaria: artesunate/amodiaquine for use in Africa and artesunate/mefloquine for use in Asia and Latin America.

Many antimalarials have become virtually useless because of resistance and most …